Vasodilators Market Report 2026

Vasodilators Market Overview

• Vasodilators market size has reached to $6.76 billion in 2025 • Expected to grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rising Cardiovascular Diseases Propel Vasodilator Market Growth • Market Trend: Innovative Inhaled Therapy Shows Promise In Improving Pulmonary Blood Flow And Managing Cardiovascular Conditions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vasodilators Market?

Vasodilators are medications that widen blood vessels by relaxing the smooth muscle cells within the vessel walls, especially in large arteries and veins. They are used to treat conditions such as hypertension (high blood pressure), angina (chest pain), and heart failure by reducing the workload on the heart and improving circulation. The main types of vasodilators are arterial dilators, venous dilators, and mixed dilators. Arterial dilators refer to medications that primarily widen the arteries, enhancing blood flow from the heart to the rest of the body. The drugs include nitroglycerin, alprostadil, minoxidil, sorbitrate, and others, and the indications are hypertension, angina, heart failure, and others. The various routes of administration include oral, parenteral, and others and are used by various end users, such as hospitals, homecare, specialty centers, and others.

What Is The Vasodilators Market Growth Forecast?

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to aging global population, rising burden of lifestyle-related diseases, expansion of specialty cardiac centers, increased focus on early diagnosis, growing access to cardiovascular medications. Major trends in the forecast period include rising prevalence of cardiovascular diseases, growing use of combination drug therapies, increased adoption of generic vasodilators, expansion of hospital-based cardiovascular care, higher demand for long-term hypertension management.

Global Vasodilators Market Segmentation

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators 2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs 3) By Indication: Hypertension, Angina, Heart Failure, Other Indications 4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users Subsegments: 1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators 2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors) 3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

What Are The Drivers Of The Vasodilators Market?

The rising prevalence of cardiovascular diseases is expected to propel the growth of the vasodilators market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increasing prevalence of cardiovascular diseases is driven by rising obesity rates, which continue to escalate due to poor diet quality and sedentary lifestyles. The vasodilators market supports the management of cardiovascular diseases by relaxing blood vessels, lowering blood pressure, and improving overall blood circulation. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the vasodilators industry. The increased adoption of sedentary lifestyles is expected to propel the growth of the vasodilators market going forward. A sedentary lifestyle refers to limited physical activity and excessive time spent sitting or lying down, often associated with minimal exercise or movement. It is increasing due to modern conveniences such as technology, transportation, and desk-bound jobs, which promote prolonged periods of inactivity. Vasodilators are used in sedentary lifestyles to improve blood flow and reduce hypertension, mitigating cardiovascular risks. For instance, in July 2023, according to the Office for National Statistics, a UK-based government department, more than 86.5% of adults in Great Britain reported making lifestyle changes to address environmental issues, based on survey responses gathered from May to June 2023. Therefore, the increased adoption of sedentary lifestyles is driving the growth of the vasodilators industry.

Key Players In The Global Vasodilators Market

Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Global Vasodilators Market Trends and Insights

Major companies operating in the vasodilators market are increasingly focusing on developing innovative solutions, such as inhaled soluble guanylate cyclase (sGC) activators, to improve pulmonary blood flow and manage cardiovascular conditions more effectively. Inhaled soluble guanylate cyclase (sGC) activators are drugs that, when inhaled, stimulate the sGC enzyme to relax blood vessels and improve blood flow, especially in the lungs. For instance, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology company, launched mosliciguat, a once-daily, inhaled sGC activator via a dry powder inhaler (DPI), developed by its subsidiary Pulmovant. Mosliciguat is formulated for lung-targeted delivery, activates sGC independent of heme and NO (which may preserve its function even under oxidative stress), and demonstrated in a Phase 1b “ATMOS” study mean‑max reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients. It was generally well tolerated, with low rates of adverse events, and its pharmacokinetic profile supports once-daily inhalation with a long half-life and limited systemic exposure. Pulmovant has initiated a global Phase 2 “PHocus” trial in ~120 patients with PH‑ILD to further assess its safety and efficacy.

Regional Insights

North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vasodilators Market?

The vasodilators market consists of sales of tablets, capsules, injectable solutions, transdermal patches, oral solutions, sublingual tablets, intravenous infusions, topical creams, and gels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vasodilators Market Report 2026?

The vasodilators market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vasodilators industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.